SCHEMBL23554237

SCHEMBL23554237

CNc1cncc(-c2csc(Nc3cccc(C(F)(F)F)c3)n2)c1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
VCP P55072 1/20 0.64
MAPT P10636 8/20 0.57
MAPK1 P28482 4/20 0.57
KDM4E B2RXH2 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
KIT P10721 2/20 0.54
CFTR P13569 2/20 0.52
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
RAB9A P51151 3/20 0.50
HTT P42858 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
ALOX5 P09917 1/20 0.50
POLB P06746 1/20 0.50
IDH2 P48735 1/20 0.49
NPC1 O15118 3/20 0.48
PKM P14618 1/20 0.48
ALDH1A1 P00352 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23539338 0.91 VCP (0.67) VCPMAPTMAPK1KDM4ENPSR1
SCHEMBL23554236 0.91 VCP (0.72) VCPMAPTMAPK1KDM4ENPSR1
SCHEMBL23691136 0.89 VCP (0.61) VCPMAPTMAPK1KDM4ENPSR1
SCHEMBL23553605 0.88 VCP (0.65) VCPMAPTMAPK1KDM4ENPSR1
SCHEMBL26308537 0.88 VCP (0.60) VCPMAPTMAPK1KDM4ENPSR1
Bromide SCHEMBL1203805 0.87 VCP (0.64) VCPMAPTMAPK1KDM4ENPSR1
SCHEMBL12157929 0.87 VCP (0.67) VCPMAPTMAPK1KDM4ENPSR1
SCHEMBL23539994 0.86 MAPT (0.65) VCPMAPTMAPK1KDM4ENPSR1
SCHEMBL23539816 0.86 VCP (0.65) VCPMAPTMAPK1KDM4ENPSR1
SCHEMBL23553606 0.86 VCP (0.65) VCPMAPTMAPK1KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021127301-A1 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS Ikena Oncology, Inc. (US) 2021-06-24 WO disclosed